Andrew J. Lucke

Andrew J. Lucke

Auto-generated profile, based on publicly available information

Andrew J. Lucke

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
KAK. T. Andrews
K. T. Andrews
TTT. N. Tran
T. N. Tran
ALA. J. Lucke
A. J. Lucke
PKP. Kahnberg
P. Kahnberg
GLG. T. Le
G. T. Le
DFD. P. Fairlie
D. P. Fairlie
The malaria parasite Plasmodium falciparum has at least five putative histone deacetylase (HDAC) enzymes, which have been proposed as new antimalarial drug targets and may play roles in regulating gene transcription, like the better-known and more intensively studied human HDACs (hHDACs). Fourteen new compounds derived from l -cysteine or 2-aminosuberic acid were designed to inhibit P. falciparum HDAC-1 (PfHDAC-1) based on homology modeling with human class I and class II HDAC enzymes. The compounds displayed highly potent antiproliferative activity against drug-resistant (Dd2) or drug sensitive (3D7) strains of P. falciparum in vitro (50% inhibitory concentration of 13 to 334 nM). Unlike known hHDAC inhibitors, some of these new compounds were significantly more toxic to P. falciparum parasites than to mammalian cells. The compounds inhibited P. falciparum growth in erythrocytes at both the early and late stages of the parasite's life cycle and caused altered histone acetylation patterns (hyperacetylation), which is a marker of HDAC inhibition in mammalian cells. These results support PfHDAC enzymes as being promising targets for new antimalarial drugs.

1 July 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SSSubathdrage D. M. Sumanadasa
Subathdrage D. M. Sumanadasa
CGChristopher D. Goodman
Christopher D. Goodman
ALAndrew J. Lucke
Andrew J. Lucke
TSTina S Skinner-Adams
Tina S Skinner-Adams
ISIshani Sahama
Ishani Sahama
KAKatherine T. Andrews
Katherine T. Andrews
Histone deacetylase (HDAC) enzymes posttranslationally modify lysines on histone and nonhistone proteins and play crucial roles in epigenetic regulation and other important cellular processes. HDAC inhibitors (e.g., suberoylanilide hydroxamic acid [SAHA; also known as vorinostat]) are used clinically to treat some cancers and are under investigation for use against many other diseases. Development of new HDAC inhibitors for noncancer indications has the potential to be accelerated by piggybacking onto cancer studies, as several HDAC inhibitors have undergone or are undergoing clinical trials. One such compound, SB939, is a new orally active hydroxamate-based HDAC inhibitor with an improved pharmacokinetic profile compared to that of SAHA. In this study, the in vitro and in vivo antiplasmodial activities of SB939 were investigated. SB939 was found to be a potent inhibitor of the growth of Plasmodium falciparum asexual-stage parasites in vitro (50% inhibitory concentration [IC 50 ], 100 to 200 nM), causing hyperacetylation of parasite histone and nonhistone proteins. In combination with the aspartic protease inhibitor lopinavir, SB939 displayed additive activity. SB939 also potently inhibited the in vitro growth of exoerythrocytic-stage Plasmodium parasites in liver cells (IC 50 , ∼150 nM), suggesting that inhibitor targeting to multiple malaria parasite life cycle stages may be possible. In an experimental in vivo murine model of cerebral malaria, orally administered SB939 significantly inhibited P. berghei ANKA parasite growth, preventing development of cerebral malaria-like symptoms. These results identify SB939 as a potent new antimalarial HDAC inhibitor and underscore the potential of investigating next-generation anticancer HDAC inhibitors as prospective new drug leads for treatment of malaria.

11 July 2011 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
MCMelissa D. Cantley
Melissa D. Cantley
Mark BartoldMark Bartold
Mark Bartold
VMV. Marino
V. Marino
DFD. P. Fairlie
D. P. Fairlie
GLG. T. Le
G. T. Le
DHD. R. Haynes
D. R. Haynes

22 February 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MCMelissa D. Cantley
Melissa D. Cantley
DFD.P. Fairlie
D.P. Fairlie
Mark BartoldMark Bartold
Mark Bartold
KRK.D. Rainsford
K.D. Rainsford
GLG.T. Le
G.T. Le
DHDavid Haynes
David Haynes

1 December 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PKPia Kahnberg
Pia Kahnberg
ALAndrew J. Lucke
Andrew J. Lucke
MGMatthew P. Glenn
Matthew P. Glenn
GBGlen M. Boyle
Glen M. Boyle
Joel TyndallJoel Tyndall
Joel Tyndall
DFDavid P. Fairlie
David P. Fairlie

1 December 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NWNicole C. Wheatley
Nicole C. Wheatley
KAKatherine T. Andrews
Katherine T. Andrews
TTTruc L. Tran
Truc L. Tran
ALAndrew J. Lucke
Andrew J. Lucke
RRRobert C. Reid
Robert C. Reid
DFDavid P. Fairlie
David P. Fairlie